"This is a time for us to rethink how we, as women in oncology, are seen in the field and how we want to position ourselves."
Nina Shah, MD
What is LEAD?
LEAD is a 2-day conference designed for women in oncology and hematology. The goal of this conference is to empower women leaders in the hematology and oncology space by providing essential clinical updates, career development, and professional networking. Sessions include discussions on the importance of women’s leadership, career development workshops, and clinical sessions on biomarkers and oncology therapies.
CO-CHAIRS
Julie Brahmer, MD, MSc
Johns Hopkins Medicine
Nina Shah, MD
University of California San Francisco
Julie M. Vose, MD, MBA
University of Nebraska Medical Center
Day 1: October 4, 2019
(7:00 AM – 7:00 PM)
PLENARY SESSION: The Importance of Women’s Leadership in Healthcare and Oncology
- Professional Vignettes and Panel Discussion
- Women oncology leaders share their journeys and perspectives on the past and current state of women in healthcare
SESSION I: Focused Workshops, Part 1
- Building Resiliency to Prevent Burnout
- Panel: Building Your Resiliency and Relationship Success
- A Social Media Toolkit to Enhance Your Career
SESSION II: Impact of Emerging Biomarkers on Treatment Selection and Drug Development
- The Role of Biomarkers in the Development of PARP Inhibitors
- When Biomarkers Define Indication — MSI, MMR, and Mutations
- Challenges with Biomarkers in Cancer Drug Development
- Panel Discussion and Participant Q&A
SESSION III and IV: Clinical Updates in Immuno-Oncology and Cell-based Therapies
- Patient Selection in Frontline Metastatic Lung Cancer
- CAR T Cell Therapy: New Era of Therapy for B-Cell Malignancies
- Targeted Tumor Treatment with Antibody Drug Conjugates
- Antibody Therapy as an Evolving SOC in Multiple Myeloma
- Immunotherapy for PD-L1 Positive or MSI-high Cervical Cancer
- Treatment Evolution in Triple Negative Breast
- Addressing Unmet Clinical Needs in Advanced Ovarian Cancer
- Panel Discussion and Participant Q&A
EVENING NETWORKING RECEPTION
Day 2: October 5, 2019
(8:00 AM – 4:00 PM)
SESSION V: Clinical Updates in Small-Molecule Targeted Inhibitors
- CLL: Reaching for Curative Potential
- Targeted Inhibitors in EGFR-positive Lung Cancer
- Moving Beyond Checkpoint Inhibition: New Treatment Options in Urothelial Cancer
- Panel Discussion and Participant Q&A
SESSION VI: Patient Management and Supportive Care in an Era of New Therapies
- Financial and Quality of Life Impact of Early Supportive Care
- Sexual Health and Fertility After Cancer Treatment for Women
- Redefining Value with Modern Cancer Therapies
- Panel Discussion and Participant Q&A
SESSION VII: Focused Workshops, Part 2
- Panel: Building Your Brand
- Panel: Leaning Into Leadership Opportunities
- Transformational Leadership
- The Future of Women in Oncology
WOMAN ONCOLOGIST OF THE YEAR and RISING STAR AWARDS